Combination therapy of infliximab and azathioprine reduces disease progression in Crohn's disease [5]

Inflammatory Bowel Diseases

Volumn 14, Issue 1, 2008, Pages 143-145

  Din, S ^a   Cochrane, C J ^a   Noble, C L ^a   Satsangi, J ^a   Arnott, I D R ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID; INFLIXIMAB;

ADULT; AGED; CONFIDENCE INTERVAL; CONTROLLED STUDY; CORTICOSTEROID THERAPY; CROHN DISEASE; DISEASE COURSE; ENTERITIS; FEMALE; FOLLOW UP; HUMAN; IMMUNOGENICITY; LETTER; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK; SEX DIFFERENCE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; AZATHIOPRINE; CROHN DISEASE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; MIDDLE AGED; TREATMENT OUTCOME;

EID: 38849147895     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1002/ibd.20260     Document Type: Letter

References (10)

1. van Dullemen HM, van Deventer SJ, Hommes DW, et al. Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2). Gastroenterology. 1995;109:129-135.
2. Hommes DW, Baert F, van Assche G, et al. Management of recent on-set Crohn's disease a controlled randomised trial comparing step-up and top-down therapy. Gastroenterology. 2005;128:A577.
3. Vermeire S, van Assche G, Rutgeerts P. Review article: altering the natural history of Crohn's disease - evidence for and against current therapies. Aliment Pharmacol Ther. 2007;25:3-12.
4. Mackey AC, Green L, Liang LC, et al. Hepatosplenic T cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2007;44:265-267.
5. Smith BR, Arnott ID, Drummond HE, et al. Disease location, anti-Saccharomyces cerevisiae antibody, and NOD2/CARD15 genotype influence the progression of disease behavior in Crohn's disease. Inflamm Bowel Dis. 2004;10:521-528.
6. Louis E, Michel V, Hugot JP, et al. Early development of stricturing or penetrating pattern in Crohn's disease is influenced by disease location, number of flares, and smoking but not by NOD2/CARD15 genotype. Gut. 2003;52:552-557.
7. Silverberg MS, Satsangi J, Ahmad T, et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol. 2005;19(Suppl A):5-36.
8. Roblin X, Serre-Debeauvais F, Phelip JM, et al. Drug interaction between infliximab and azathioprine in patients with Crohn's disease. Aliment Pharmacol Ther. 2003;18:917-925.
9. Lichtenstein GR, Feagan BG, Cohen RD, et al. Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry. Clin Gastroenterol Hepatol. 2006;4:621-630.
10. Johnson FR, Ozdemir S, Mansfield C, et al. Crohn's disease patients' risk-benefit preferences: serious adverse event risks versus treatment efficacy. Gastroenterology. 2007 (in press).